High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results.
In summary, the administration of effective high-dose chemotherapy regimens at a time of minimal tumor burden should eradicate disease in selected breast cancer patients who otherwise have little chance of prolonged disease-free survival following standard-dose treatments. The results are particularly promising for breast cancer patients with high-risk stage II/III, and NED or responsive stage IV disease. Many studies to confirm these hypotheses are in progress. New high-dose chemotherapy regimens, together with methods to reduce tumor contamination of the graft and new treatment modalities should improve the current results in patients with breast cancer.
Cagnoni
P J
PJ
University of Colorado Bone Marrow Transplant Program, Denver, USA.
Shpall
E J
EJ
Bearman
S I
SI
Ross
M
M
Jones
R B
RB
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001781:Blood Component Removal / Q000379:methods; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000628:therapy*; D002986:Clinical Trials as Topic; D003120:Colorado; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009360:Neoplastic Cells, Circulating; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous